Glyph

PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers

Retrieved on: 
Tuesday, November 14, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, CNS, Allopregnanolone, Schizophrenia, Daphne, Trier social stress test, PureTech Health, Anxiety, Neurosteroid, Patient, Multimedia, LSE, KarXT, Alprazolam, PRTC, Psychiatry, FRCPC, Epilepsy, Pharmacology, Therapy, Benzodiazepine, Stress-related disorders, DSM-IV codes, MPH, University, TSST, Massachusetts General Hospital, Public health, Glyph, Central nervous system, Volunteering, Hospital, Pharmaceutical industry, MD

The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.

Key Points: 
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • View the full release here: https://www.businesswire.com/news/home/20231113556006/en/
    PureTech announced topline results from its Phase 2a, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone).
  • The trial was designed to evaluate the salivary cortisol response in the Trier Social Stress Test (TSST), a validated clinical model of anxiety in healthy volunteers.
  • An increase in cortisol levels after the TSST is a physiological response and an objective biomarker of acute stress.

PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

Retrieved on: 
Tuesday, August 1, 2023
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, PRTC, LSE, Defense Health Agency, University of California, Davis, Tremor, Anxiety, University, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, Ageing, PureTech Health, FMR1, Research, Medicine, Development director, Element, Veteran, CNS, Dementia, Trial of the century, Science, Assistant, Intellectual disability, FXS, Fragile X syndrome, UC, Patient, Department of Defense Serum Repository, United States Army Medical Research and Development Command, Spectrum, United States Army Medical Research Institute of Infectious Diseases, MIND Institute, FXTAS, Office of the Assistant Secretary for Health, Assistant Secretary of Defense for Health Affairs, Glyph, Cannabidiol, Safety, Allopregnanolone, Pharmaceutical industry, Vaccine, Defense, Fragile

The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).

Key Points: 
  • The funds will support a Phase 2 trial of LYT-300 in collaboration with the University of California, Davis (UC Davis).
  • Both conditions are the result of repeated elements in the Fragile X Messenger Ribonucleoprotein Gene 1 (FMR1) gene.
  • Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.
  • In addition to LYT-300, which is being advanced in three indications, PureTech is progressing multiple CNS-focused programs derived from its Glyph platform.

Nothing Introduces Phone (2)

Retrieved on: 
Tuesday, July 11, 2023
Human, Life, Journal of Electronic Imaging, Smartphone, Aluminium, Sony, ISP, OS, Image, EIS, CAD, Mah, Software design, Glyph, LED, Forest Stewardship Council, OIS, Algorithm, OLED, Education minister, MP, Tin, RAW, FSC, CO2, Software, Mobile phone, Typesetting, Television, Recycling, Printed circuit board

LONDON, July 11, 2023 /PRNewswire/ -- Nothing today announced Phone (2), its highly anticipated second-generation flagship smartphone. Engineered to make smartphone usage more mindful, Phone (2) introduces the new Glyph Interface at the back, enabling users to minimize screen interactions by accessing key information at a glance. It also features a revamped Nothing OS 2.0, rooted in utility and designed to reduce distractions, while delivering a fast and smooth experience that embodies Nothing's unique aesthetics. Powered by the top-of-the-line Snapdragon® 8+ Gen 1 Mobile Platform, Phone (2) delivers Nothing's most premium smartphone experience to date, boasting a powerful 50MP dual rear camera with advanced algorithms for true-to-life photography, and a stunning 6.7-inch OLED display with LTPO.

Key Points: 
  • Phone (2) evolves the smartphone experience to be more mindful and intentional, while delivering best-in-class features
    LONDON, July 11, 2023 /PRNewswire/ -- Nothing today announced Phone (2), its highly anticipated second-generation flagship smartphone.
  • Engineered to make smartphone usage more mindful, Phone (2) introduces the new Glyph Interface at the back, enabling users to minimize screen interactions by accessing key information at a glance.
  • Nothing has meticulously engineered Phone (2) with obsessive attention to detail, delivering a refined version of its first-generation smartphone, Phone (1).
  • Equipped with an advanced 18-bit Image Signal Processor (ISP), Phone (2) has the ability to process camera data up to 4,000 times more than its predecessor, Phone (1).

Nothing Introduces Phone (2)

Retrieved on: 
Tuesday, July 11, 2023
Human, Stick, Life, Journal of Electronic Imaging, Smartphone, Aluminium, Sony, ISP, OS, Image, EIS, Mah, Software design, Glyph, LED, Forest Stewardship Council, OIS, Algorithm, OLED, Education minister, MP, United Kingdom, GBP, Tin, RAW, FSC, CO2, Software, Mobile phone, Typesetting, Television, Recycling, Printed circuit board

LONDON, July 11, 2023 /PRNewswire/ -- Nothing today announced Phone (2), its highly anticipated second-generation flagship smartphone. Engineered to make smartphone usage more mindful, Phone (2) introduces the new Glyph Interface at the back, enabling users to minimize screen interactions by accessing key information at a glance. It also features a revamped Nothing OS 2.0, rooted in utility and designed to reduce distractions, while delivering a fast and smooth experience that embodies Nothing's unique aesthetics. Powered by the top-of-the-line Snapdragon® 8+ Gen 1 Mobile Platform, Phone (2) delivers Nothing's most premium smartphone experience to date, boasting a powerful 50MP dual rear camera with advanced algorithms for true-to-life photography, and a stunning 6.7-inch OLED display with LTPO.

Key Points: 
  • Phone (2) evolves the smartphone experience to be more mindful and intentional, while delivering best-in-class features
    LONDON, July 11, 2023 /PRNewswire/ -- Nothing today announced Phone (2), its highly anticipated second-generation flagship smartphone.
  • Engineered to make smartphone usage more mindful, Phone (2) introduces the new Glyph Interface at the back, enabling users to minimize screen interactions by accessing key information at a glance.
  • Nothing has meticulously engineered Phone (2) with obsessive attention to detail, delivering a refined version of its first-generation smartphone, Phone (1).
  • Equipped with an advanced 18-bit Image Signal Processor (ISP), Phone (2) has the ability to process camera data up to 4,000 times more than its predecessor, Phone (1).

Nothing Introduces Phone (2)

Retrieved on: 
Tuesday, July 11, 2023
Human, Life, Journal of Electronic Imaging, Smartphone, Aluminium, Sony, ISP, OS, Image, EIS, CAD, Mah, Software design, Glyph, LED, Forest Stewardship Council, OIS, Algorithm, OLED, Education minister, MP, Tin, RAW, FSC, CO2, Software, Mobile phone, Typesetting, Television, Recycling, Printed circuit board

LONDON, July 11, 2023 /PRNewswire/ -- Nothing today announced Phone (2), its highly anticipated second-generation flagship smartphone. Engineered to make smartphone usage more mindful, Phone (2) introduces the new Glyph Interface at the back, enabling users to minimize screen interactions by accessing key information at a glance. It also features a revamped Nothing OS 2.0, rooted in utility and designed to reduce distractions, while delivering a fast and smooth experience that embodies Nothing's unique aesthetics. Powered by the top-of-the-line Snapdragon® 8+ Gen 1 Mobile Platform, Phone (2) delivers Nothing's most premium smartphone experience to date, boasting a powerful 50MP dual rear camera with advanced algorithms for true-to-life photography, and a stunning 6.7-inch OLED display with LTPO.

Key Points: 
  • Phone (2) evolves the smartphone experience to be more mindful and intentional, while delivering best-in-class features
    LONDON, July 11, 2023 /PRNewswire/ -- Nothing today announced Phone (2), its highly anticipated second-generation flagship smartphone.
  • Engineered to make smartphone usage more mindful, Phone (2) introduces the new Glyph Interface at the back, enabling users to minimize screen interactions by accessing key information at a glance.
  • Nothing has meticulously engineered Phone (2) with obsessive attention to detail, delivering a refined version of its first-generation smartphone, Phone (1).
  • Equipped with an advanced 18-bit Image Signal Processor (ISP), Phone (2) has the ability to process camera data up to 4,000 times more than its predecessor, Phone (1).

PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

Retrieved on: 
Tuesday, February 14, 2023
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Allopregnanolone, LSE, Social anxiety, Woman, Therapy, Village development committee (Nepal), PPD, PureTech Health, Patient, Clinical trial, Depression, Anxiety, PRTC, GABAA, Multimedia, R, Pharmaceutical industry, Vaccine, Glyph

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that it will advance LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that it will advance LYT-300 (oral allopregnanolone) for the potential treatment of anxiety disorders and postpartum depression (PPD).
  • An open-label, Phase 2a, proof-of-concept clinical trial in women with PPD is expected to initiate in the second half of 2023.
  • “Using our proprietary Glyph™ platform, we have made natural allopregnanolone orally bioavailable without permanently chemically modifying the natural neurosteroid.
  • It has demonstrated a rapid onset of action for the treatment of depression, as well as the potential to treat other neurological conditions, including anxiety, but its poor oral bioavailability has limited its therapeutic potential.

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Retrieved on: 
Monday, December 19, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Lymphatic system, PAM, Annual report, Patient, U.S. FDA, Journal of the Neurological Sciences, Monash University, Benzodiazepine, University of Melbourne, Disorder, Liver, Immune system, Journal, Environment, Depression, Evaluation, Angewandte Chemie, Kathryn Bullock, PRTC, Drug development, Pharmacy, Allopregnanolone, FDA, Safety, Clinical trial, PPD, LSE, CDER, GABA, Multimedia, Fat, Food, PureTech Health, Pharmacology, Parkinson's disease, Monash Institute of Medical Research, Therapy, Journal of Controlled Release, Platform supply vessel, GABAA, Research, Control, Pharmaceutical industry, Vaccine, CBD, Glyph, List of Nature Research journals

View the full release here: https://www.businesswire.com/news/home/20221219005209/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221219005209/en/
    PureTech announced topline results for LYT-300 (oral allopregnanolone), a therapeutic candidate in development for neurological and neuropsychological conditions.
  • The results show that oral administration of LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic benefit and results in exposure-dependent target engagement of GABAA receptors.
  • The impact of LYT-300 on b-EEG and other markers of GABAA target engagement were also assessed.
  • PureTech completed a Phase 1 clinical trial of LYT-300 in 2022, which demonstrated oral bioavailability, tolerability and GABAA receptor target engagement in healthy volunteers.

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Retrieved on: 
Wednesday, November 30, 2022
Research, FDA, Clinical Trials, Health Technology, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Science, Epilepsy, Environment, Monash Institute of Medical Research, PureTech Health, Immune system, Pharmacy, Fat, Multimedia, Doctor of Philosophy, Control, University of Melbourne, Safety, Annual report, Liver, PRTC, LSE, Monash University, Lymphatic system, Drug development, GI, Journal of Controlled Release, Journal, Therapy, Research, Platform supply vessel, U.S. FDA, Seizure, FDA, Angewandte Chemie, Pharmaceutical industry, Dietary supplement, Glyph, Nature Medicine, CBD

View the full release here: https://www.businesswire.com/news/home/20221130005402/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221130005402/en/
    PureTech announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTechs Glyph platform to be advanced toward the clinic.
  • The nomination of LYT-310 is an exciting expansion of PureTechs Glyph technology, said Daniel Bonner, Ph.D., Vice President at PureTech Health.
  • Glyph is PureTechs synthetic lymphatic-targeting chemistry platform which is designed to employ the lymphatic systems natural lipid absorption and transport process to enable the oral administration of certain therapeutics.
  • A second therapeutic candidate, LYT-310 (oral cannabidiol), is expected to enter the clinic in Q4 of 2023.

Pure Instinct. This is Nothing Phone (1)

Retrieved on: 
Tuesday, July 12, 2022
Power, Friends, Family, Visual language, Tesla, Sony, Antirrhinum, CEO, Qualcomm, OLED, OS, Instinct, MP, Light-emitting diode, AC, Flip, Smartphone, Collection, Rest, GB, Twitter, Mark (given name), Game, Industry, Covent Garden, Typesetting, Mobile phone, Glyph, Android, Instagram, Discord

LONDON, July 12, 2022 /PRNewswire/ -- Today Nothing introduced Phone (1), its first smartphone and the gateway to its future connected and open product ecosystem. Featuring the innovative Glyph Interface, a 50 MP dual camera, refined Nothing OS, 120Hz OLED display and a co-engineered Qualcomm® Snapdragon™ 778G+ chipset, Nothing Phone (1) delivers speed and a smooth experience from £399 GBP. With a 200,000+ pre-order waitlist, and bids over $3,000 USD for the first 100 serialised units, it's one of the most anticipated tech products in years.

Key Points: 
  • LONDON, July 12, 2022 /PRNewswire/ --Today Nothing introduced Phone (1), its first smartphone and the gateway to its future connected and open product ecosystem.
  • "We designed Phone (1) as a product we'd be proud to share with friends and family," said Carl Pei, CEO and Co-founder of Nothing.
  • For quieter focus, the Flip to Glyph feature triggers silent, lights-only notifications by placing Phone (1) with the Glyph Interface face up.
  • In the UK, Phone (1) will also be available from the following:
    Nothing Kiosk (16 - 20 July) in Seven Dials, Covent Garden, London.

Pure Instinct. This is Nothing Phone (1)

Retrieved on: 
Tuesday, July 12, 2022
Power, Friends, Family, Visual language, Tesla, Sony, Antirrhinum, CEO, Qualcomm, OLED, OS, Instinct, MP, Light-emitting diode, AC, Flip, Smartphone, Collection, Rest, GB, Twitter, Mark (given name), Game, Industry, Covent Garden, Typesetting, Mobile phone, Glyph, Android, Instagram, Discord

LONDON, July 12, 2022 /PRNewswire/ -- Today Nothing introduced Phone (1), its first smartphone and the gateway to its future connected and open product ecosystem. Featuring the innovative Glyph Interface, a 50 MP dual camera, refined Nothing OS, 120Hz OLED display and a co-engineered Qualcomm® Snapdragon™ 778G+ chipset, Nothing Phone (1) delivers speed and a smooth experience from £399 GBP. With a 200,000+ pre-order waitlist, and bids over $3,000 USD for the first 100 serialised units, it's one of the most anticipated tech products in years.

Key Points: 
  • LONDON, July 12, 2022 /PRNewswire/ --Today Nothing introduced Phone (1), its first smartphone and the gateway to its future connected and open product ecosystem.
  • "We designed Phone (1) as a product we'd be proud to share with friends and family," said Carl Pei, CEO and Co-founder of Nothing.
  • For quieter focus, the Flip to Glyph feature triggers silent, lights-only notifications by placing Phone (1) with the Glyph Interface face up.
  • In the UK, Phone (1) will also be available from the following:
    Nothing Kiosk (16 - 20 July) in Seven Dials, Covent Garden, London.